Takeda Pharmaceutical Company Limited TAK
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -209.03% | -226.21% | -43.21% | -86.54% | -1.63% |
| Total Depreciation and Amortization | -9.89% | -4.48% | -1.32% | -2.40% | -0.94% |
| Total Amortization of Deferred Charges | 2.23% | 2.23% | 20.80% | 20.80% | 20.80% |
| Total Other Non-Cash Items | 61.56% | 9.59% | 146.97% | 286.41% | 1,371.93% |
| Change in Net Operating Assets | 424.57% | 422.97% | -3,506.34% | 130.09% | 85.67% |
| Cash from Operations | -14.86% | -0.06% | 7.59% | 37.23% | 37.79% |
| Capital Expenditure | 8.21% | 11.23% | 7.95% | 7.64% | -2.47% |
| Sale of Property, Plant, and Equipment | -83.61% | 8,564.74% | 13,863.39% | 2,042.95% | -24.95% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -71.22% | 69.21% | 52.36% | 52.53% | 111.70% |
| Other Investing Activities | -135.47% | -25.09% | 16.23% | 57.54% | 46.11% |
| Cash from Investing | -68.77% | -0.81% | 18.87% | 40.73% | 30.94% |
| Total Debt Issued | -44.70% | -44.29% | -45.81% | -48.45% | 7.89% |
| Total Debt Repaid | 71.96% | 57.18% | 36.30% | -68.18% | -329.24% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 99.01% | 0.50% | -5,297.50% | -5,297.50% | -5,297.50% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 2.91% | -6.26% | -6.79% | -7.05% | -7.12% |
| Other Financing Activities | -5.30% | -62.40% | -64.40% | -87.93% | -718.44% |
| Cash from Financing | 65.27% | 33.66% | -40.95% | -3,442.56% | -534,540.79% |
| Foreign Exchange rate Adjustments | 233.81% | 368.66% | 208.29% | 232.77% | -212.44% |
| Miscellaneous Cash Flow Adjustments | -101.52% | -196.97% | -- | -- | -4.35% |
| Net Change in Cash | 128.53% | 380.59% | -16.62% | -131.24% | -193.97% |